Abstract:Background Emerging metabolomics-based studies suggested links between amino acids metabolism and non-alcoholic fatty liver disease (NAFLD) risk, however, whether there exists an aetiological role of amino acid metabolism in NAFLD development remains unknown. The aim of the present study was to assess the causal relationship between circulating levels of amino acids and NAFLD risk.Methods We performed two-sample Mendelian randomisation (MR) analyses using summary level data from genome-wide association studies (GWAS) to assess causal relationships between genetically predicted circulating levels of amino acids and NAFLD risk. Data from the largest GWAS on NAFLD (8,434 cases and 770,180 controls) were used in discovery MR analysis, and from a GWAS on NAFLD (1,483 cases and 17,781 controls) where NAFLD cases were diagnosed using liver biopsy, were used in replication MR analysis. Wald ratios or multiplicative random-effect inverse variance weighted (IVW) methods were used in the main MR analysis, and weighted median and MR-Egger regression analysis were used in sensitivity analyses. We additionally performed an MR conservative analysis by restricting genetic instruments to those directly involved in amino acid metabolism pathways.Findings We found that genetically predicted higher alanine (OR=1.45, 95% CI 1.15-1.83) and lower glutamine (OR = 0.81, 95% CI 0.66-1.00) levels were associated with a higher risk of developing NAFLD. Results from MR sensitivity analyses and conservative analysis supported the main findings.Interpretation Genetically predicted higher circulating levels of alanine was associated with an increased risk of NAFLD, whereas higher glutamine was associated with a decreased risk of NAFLD.Funding This work was supported by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (2021YJRC02).Evidence before this study Recent metabolomics studies revealed associations between circulating levels of several amino acids and non-alcoholic fatty liver disease (NAFLD) risk. Most of these studies were conducted with a focus on the profiling of amino acids between individuals with NAFLD and healthy subjects, which suggested the altered amino acid metabolism might be a consequence of NAFLD rather than a causal risk factor for NAFLD. We searched PubMed for studies in any language using the search terms “amino acids” AND “Non-alcoholic fatty liver disease OR NAFLD OR fatty liver” AND “Mendelian randomisation OR Mendelian randomization”, and found few studies on the causal effects of circulating amino acids on NAFLD risk. Thus, whether there is an aetiological role of amino acids in NAFLD development remains unknown.Added value of this study In the present study, we systematically investigated the causal effects of genetically predicted circulating levels of 20 amino acids on NAFLD risk using data from large-scale genome-wide association studies in up to 778,614 individuals of European ancestry. We utilised a state-of-art causal inference approach, that is Mendelian randomisation, to construct layers of evidence. Overall, we found that among 20 amino acids, genetically predicted higher circulating levels of alanine was associated with an increased risk of NAFLD, whereas higher glutamine was associated with a decreased risk of NAFLD.Implications of all the available evidence Our study is the first to systematically assess the causal relationships between levels of plasma amino acids and the development of NAFLD using multi-omics (i.e., genomic and metabolomic) data from large-scale human studies. Our results suggest the potential for the glutamine supplementation or alanine depletion for personalized nutrition in NAFLD prevention and treatment.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementThis study was supported by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (2021YJRC02).### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study only used summary level data from relevant GWASs. Genetic association estimates for amino acids were obtained by accessing to omicscience web (https://omicscience.org). The summary statistics on NAFLD were obtained from GWASs conducted by Ghodsian et al. and Anstee et al., which had been deposited at the GWAS catalog (https://www.ebi.ac.uk/gwas/). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenetic association estimates for amino acids were obtained by accessing to omicscience web (https://omicscience.org). The summary statistics on NAFLD were obtained from GWASs conducted by Ghodsian et al. and Anstee et al., which had been deposited at the GWAS catalog (https://www.ebi.ac.uk/gwas/).

Metabolites mediate the causal associations between gut microbiota and NAFLD: a Mendelian randomization study

Metabolites Mediate the Causal Associations Between Gut Microbiota and NAFLD：a Mendelian Randomization Study

Investigating causal associations among gut microbiota, metabolites, and liver diseases: a Mendelian randomization study

Association Between Gut Microbiota and NAFLD/NASH: a Bidirectional Two-Sample Mendelian Randomization Study

Immune Cells and Blood Lipids Mediation: a Mendelian Randomization Study on Metabolic Dysfunction-Associated Fatty Liver Disease

Association between the gut microbiota and nonalcoholic fatty liver disease: A two-sample Mendelian randomization study

Impact of gut microbiota on nonalcoholic fatty liver disease: insights from a leave-one-out cross-validation study

Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome

Association between circulating biomarkers and non-alcoholic fatty liver disease: An integrative Mendelian randomization study of European ancestry

Causal relationships between the gut microbiota, inflammatory cytokines, and alcoholic liver disease: a Mendelian randomization analysis

Iron Status and NAFLD among European Populations: A Bidirectional Two-Sample Mendelian Randomization Study

Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-Alcoholic Fatty Liver Disease

The Causality Between Gut Microbiome and Liver Cirrhosis: a Bi-Directional Two-Sample Mendelian Randomization Analysis

Dissecting the association between gut microbiota and liver cancer in European and East Asian populations using Mendelian randomization analysis

Causal Relationships Between Genetically Predicted Circulating Levels of Amino Acids and Non-Alcoholic Fatty Liver Disease Risk: a Mendelian Randomisation Study

Assessment of causal associations among gut microbiota, metabolites, and celiac disease: a bidirectional Mendelian randomization study

The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study

Causal Relationships Between Gut Metabolites and Alzheimer's Disease: a Bidirectional Mendelian Randomization Study.

Mendelian randomization explores the causal relationships between obesity, diabetes, inflammation and nonalcoholic fatty liver disease

Roles of Human Gut Microbiota in Liver Cirrhosis Risk: A Two-Sample Mendelian Randomization Study.

Gut microbiota, circulating metabolites, and gallstone disease: a Mendelian randomization study